Objective
Does the use of nifedipine and magnesium sulfate together increase serious magnesium-related
effects?
Study design
This was a retrospective chart review of women who were admitted to BC Women's Hospital
and Health Centre (1997-2001) and were given intravenous magnesium sulfate for preeclampsia.
Serious magnesium-related effects were compared among 162 cases who received magnesium
sulfate and contemporaneous nifedipine and 215 control subjects who received magnesium
sulfate and either another antihypertensive (n = 32 women) or no antihypertensive (n = 183 women) medication. Chi-squared test, Fisher's exact test, or the Student t test was used for data comparison between cases and each control group. A probability
value of <.05 was considered statistically significant.
Results
The cases had more severe preeclampsia and a longer magnesium sulfate infusion. However,
cases had no excess of neuromuscular weakness (53.1%) versus control subjects who
received antihypertensive medication (53.1%; P = .99) or control subjects who received no antihypertensive medication (44.8%; P = .13) or other serious magnesium-related effects. Cases versus control subjects who
received antihypertensive medication had less neuromuscular blockade (odds ratio,
0.04; 95% CI, 0.002-0.80). Cases versus control subjects who received no antihypertensive
medication had less maternal hypotension (41.4% vs 53.0%; P = .04).
Conclusion
The use of nifedipine and magnesium sulfate together does not increase the risk of
serious magnesium-related effects.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Report of the Canadian Hypertension Society Consensus Conference: 3, pharmacologic treatment of hypertensive disorders in pregnancy.CMAJ. 1997; 157: 1245-1254
- The detection, investigation and management of hypertension in pregnancy: executive summary.Aust N Z J Obstet Gynaecol. 2000; 40: 133-138
- Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.Am J Obstet Gynecol. 2000; 183: S1-S22
- The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade.Br J Obstet Gynaecol. 1994; 101: 262-263
- Neuromuscular blockade with magnesium-sulfate and nifedipine.Am J Obstet Gynecol. 1989; 161: 35-36
- Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks.BJOG. 1993; 100: 959-961
- Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia?.Am J Obstet Gynecol. 1988; 159: 308-309
- Fortnightly review: management of hypertension in pregnancy.BMJ. 1999; 318: 1332-1336
- Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.BMJ. 2003; 327: 955-960
- The calcium antagonist controversy: a posthumous commentary.Am J Cardiol. 1998; 82: 35R-39R
- Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study.J Obstet Gynaecol Can. 2003; 25: 372-382
- Why mothers die 1997-1999: the confidential enquiries into maternal deaths in the UK.RCOG Press, London2001
- Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.Lancet. 2002; 359: 1877-1890
- Report of the Canadian Hypertension Society Consensus Conference: 1, definitions, evaluation and classification of hypertensive disorders in pregnancy.CMAJ. 1997; 157: 715-725
- Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.Acta Obstetricia et Gynecologica Scand. 2002; 81: 25-30
- Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.Intens Care Med. 2002; 28: 1281-1286
- Nifedipine in the treatment of severe preeclampsia.Obstet Gynecol. 1991; 77: 331-337
- Oral nifedipine therapy in the management of severe preeclampsia.Int J Gynaecol Obstet. 1995; 49: 265-269
- Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension.Clin Exper Hypertens Pregn. 1992; B11: 25-44
- A Randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.Am J Obstet Gynecol. 1999; 181: 858-861
- Sublingual nifedipine compared with intravenous hydralazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice.J Obstet Gynaecol Res. 1996; 22: 21-24
- Nifedipine in acute hypertensive emergencies in pregnancy.S Afr Med J. 1989; 76: 248-250
- Pre-eclampsia severa: nifedipina versus cloropromazina en el manejo del estado hipertensivo agudo.Rev Med IMSS. 1989; 27: 359-363
- Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension.Aust N Z J Obstet. Gynaecol. 1992; 32: 335-338
- A comparative study of intravenous isradipine and dihydralazine in the treatment of severe hypertension of pregnancy in black patients.Hypertens Pregn. 1997; 16: 1-9
- Manejo de la preeclampsia severa/eclampsia. comparacion entre nifedipine e hidralazina como medicamentos antihipertensivos.Ginec Obst Mex. 1993; 61: 76-79
Article info
Publication history
Accepted:
November 24,
2004
Received:
October 25,
2004
Footnotes
Supported by the British Columbia Research Institute for Children's and Women's Health, the Michael Smith Foundation for Health Research (L.A.M), and Drs. Magee and von Dadelszen receive research support from the British Columbia Research Institute for Children's and Women's Health, and the BC Women's Hospital Foundation (L.A.M. and P.vD.).
Identification
Copyright
© 2005 Mosby, Inc. Published by Elsevier Inc. All rights reserved.